<DOC>
	<DOCNO>NCT01672554</DOCNO>
	<brief_summary>This research explore whether Quetiapine XR use primarily treat psychosis may also cover comorbid anxiety disorder offer advantage patient schizophrenia comorboid anxiety disorder . Preliminary data pharmacological property Quetiapine metabolite intuitive impression clinical experience lead believe Seroquel XR use monotherapy may offer advantage antipsychotic treat co-morbid anxiety disorder patient suffer schizophrenia . This open label switch study conduct schizophrenic population intend verify hypothesis .</brief_summary>
	<brief_title>Clinical Benefits Seroquel XR Anxiety Disorder</brief_title>
	<detailed_description>This open label , non-randomised , single arm phase IIIB study . Patients enrol study current antipsychotic medication provide optimal control psychopathology symptom , judge investigator . Therefore , patient switch current effective well tolerate antipsychotic regimen study drug sole reason enrol study . After enrolment , patient switch Quetiapine XR follow intent-to-treat design 6 month . Even patient stop reason Quetiapine XR require add adjust antidepressant anxiety resistant symptom , he/she assess entire study . Data analyse separately . Quetiapine XR titrate accord follow pattern : Seroquel XR 300 mg day 1 Seroquel XR 600 mg day 2 . On day 3 , dosage could either maintain 600 mg/day continue 800 mg/day 600 mg dose tolerate , dose could reduce 400 mg/day . Following , subject flexibly dose , accord clinical judgment investigator , 400 mg/day 800 mg/day minimum dose adjustment 200 mg/day . This adjustment perform anytime study take place within week last cognitive assessment , plan month 6 . An overlap least 4 day 2 week previous antipsychotic allow decreasing dos two-week period .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent ; A diagnosis schizophrenia schizophrenia spectrum psychosis ( schizophreniform , schizoaffective , delusional disorder , brief psychosis ) define Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) ; Presenting comorbid anxiety disorder well control current pharmacological treatment accord investigator correspond DSMIV ; Having initial score 20 enrolment HAMA scale ; Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrolment ; Patient antidepressant benzodiazepine recently ( last 4 week ) introduce , request dose adjustment last 4 week ; Patient anticholinergic take regular basis ; Patient receive one antipsychotic ; Pregnancy lactation ; Any DSMIV Axis I disorder define inclusion criterion ; Patients , opinion investigator , pose imminent risk suicide danger self others ; Known intolerance lack response Quetiapine fumarate , judge investigator ; Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir ; Use follow cytochrome P450 inducers 14 day precede enrolment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid ; Administration depot antipsychotic injection within one dose interval ( depot ) enrolment ; Substance alcohol dependence enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion ; Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrolment ; Medical condition would affect absorption , distribution , metabolism , excretion study treatment ; Unstable inadequately treat medical illness ( e.g . congestive heart failure , angina pectoris , hypertension ) judge investigator ; Involvement plan conduct study ; Previous enrolment treatment present study ; Participation phase IIIIII drug trial within 4 week prior enrolment study long accordance local requirement ; A patient Diabetes Mellitus ( DM ) An absolute neutrophil count ( ANC ) 1.5 x 109 per liter ; An ALTAST count 3 x ULN and/or Bilirubin count 1.5 x ULN ; Any clinically significant laboratory abnormality , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Anxiety disorder</keyword>
</DOC>